Investors

Kadimastem on Tel-Aviv Stock Exchange

October 29, 2025 at 1:57:59 PM

October 27, 2025 at 11:34:36 AM

October 23, 2025 at 10:19:09 AM

September 30, 2025 at 11:37:32 AM

September 10, 2025 at 10:04:32 AM

September 4, 2025 at 12:05:57 PM

July 17, 2025 at 11:46:35 AM

June 16, 2025 at 11:53:04 AM

March 31, 2025 at 12:19:07 PM

February 25, 2025 at 12:00:21 PM

February 10, 2025 at 12:46:04 PM

January 16, 2025 at 3:06:16 PM

January 8, 2025 at 12:39:41 PM

December 31, 2024 at 8:57:53 AM

December 19, 2024 at 12:21:18 PM

November 27, 2024 at 8:52:50 AM

November 17, 2024 at 7:37:23 AM

November 5, 2024 at 7:34:17 AM

October 29, 2024 at 8:05:32 AM

July 29, 2024 at 11:11:06 AM

June 23, 2024 at 7:08:03 AM

February 28, 2024 at 2:10:37 PM

February 14, 2024 at 10:00:00 PM

February 7, 2024 at 10:44:02 AM

January 24, 2024 at 10:00:00 PM

January 22, 2024 at 8:10:35 AM

November 7, 2023 at 7:16:58 AM

June 20, 2023 at 7:32:57 AM

May 15, 2023 at 11:10:42 AM

May 9, 2023 at 6:16:05 AM

Investors

Investors

For More Investors Info.

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

Kadimastem Announces Strategic Collaboration with TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

The BIRD Foundation Approves Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

Kadimastem Shares that NLS Pharmaceutics CEO Issues Letter to Shareholders

Kadimastem and NLS Pharmaceutics Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes

Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements

Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge

The World Prestigious Diabetes Research Institute, University of Miami, Announces Kadimastem's Joint Project as Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC

Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA

Kadimastem and iTolerance Submit INTERACT Request with FDA for Potential Cure for Type 1 Diabetes

Kadimastem Receives US Patent for Its Cell Selection & Enrichment Technology Used to Develop IsletRx

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation